Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPC6 | Q9Y210 | 5/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 10/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 6/20 | 0.40 |
| ▸ | PDE4A | P27815 | 4/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.39 |
| ▸ | FDPS | P14324 | 1/20 | 0.39 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15351087 | 0.84 | CNR2 (0.38) | TRPC6 | |
| SCHEMBL1223854 | 0.81 | ALDH1A1 (0.47) | FDPS | |
| SCHEMBL29911113 | 0.78 | KMO (0.46) | PDE4BPDE4DPDE4A | |
| SCHEMBL24046766 | 0.78 | FDPS (0.42) | FDPS | |
| SCHEMBL637014 | 0.78 | FDPS (0.67) | PDE4BPDE4DPDE4APDE4CFDPS | |
| SCHEMBL21045798 | 0.77 | TRPC6 (0.55) | TRPC6 | |
| SCHEMBL24046927 | 0.76 | KDM4E (0.49) | PDE4BPDE4DPDE4APDE4CFDPS | |
| SCHEMBL33374298 | 0.75 | TRPC6 (0.45) | TRPC6FDPS | |
| SCHEMBL21045633 | 0.75 | TRPC6 (0.54) | TRPC6 | |
| SCHEMBL30439691 | 0.75 | TRPC6 (0.54) | TRPC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230137816-A1 | ADMINISTRATION OF CALCIUM CHANNEL TRPC6 INHIBITORS USING BALLOONS, STENTS OR OTHER MEDICAL DEVICES | DEUTSCHES HERZZENTRUM MUENCHEN DES FREISTAATES BAYERN (DE) | 2023-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230137816-A1 | ADMINISTRATION OF CALCIUM CHANNEL TRPC6 INHIBITORS USING BALLOONS, STENTS OR OTHER MEDICAL DEVICES | TRPC6, TRPC1, ORAI1 | TRPC6 1/4885PDE4B 1921/4885PDE4D 2078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.